Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
Gilead has conducted an analysis of genetic information currently available for the Omicron variant and found no additional prevalent mutations
Tag: coronavirus
An interesting hypothesis: CD‐sACE2 inclusion compounds to treat COVID‐19
Angiotensin‐converting enzyme 2 (ACE2) has been identified as the main receptors for SARS‐CoV and SARS‐CoV‐2. Soluble ACE2 (sACE2) can bind
A cheap and widely available steroid, dexamethasone can help save the lives of patients seriously ill with coronavirus
Researchers led by Professor Peter Horby at the University of Oxford, in England say they have the first evidence that
Vaccines against COVID-19
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Coronavirus and COVID-19: The latest news and views from the scientific community about the new coronavirus and Covid-19
Coronavirus is a family of viruses that cause respiratory infections.The new coronavirus agent was discovered on 12/31/19 after cases registered
Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
UC Berkeley, Excivion and CycloLab develop antiviral cyclodextrins against SARS-CoV-2
UC Berkeley, Excivion and Cyclolab announce a supplemental grant awarded to UC Berkeley by the National Institutes of Health to evaluate a wide